

Dated: 18 December 2019

Indices	CMP	%1D
Sensex	41352	1.01
Nifty	12165	0.92
BSE-Midcap	14818	0.38
BSE-Smallcap	13393	0.66
SGX Nifty	12194	0.02

### Market Outlook

Indian markets indicates for a possible positive opening by forming a bullish candle on the daily charts based on technicals. As the momentum is positive, the index is expected to march further and cross 12,200 levels in the coming sessions. Globally Asian markets are subdued today despite S&P 500 eked out the record highs. Back home technically the key support level for Nifty is placed at 12,095., followed by 12,026. If the index moves up, key resistance levels to watch out for are 12,208 and 12,251.

Index	FY20	FY21E	FY22E
Sensex EPS	1402	1985	2244
P/E	29	20	18
Nifty EPS	458	603	688
P/E	26	20	17

### Top Domestic News

- Allahabad Bank: CRISIL assigned AA-/Rating Watch With Negative implications to Tier-II bonds worth Rs 1,500 crore.
- Prestige Estates: Board to consider raising funds via preferential issue of shares on December 20.
- Zee Entertainment: Brickwork revised rating on 6% cumulative redeemable preference shares to AA from AA+.
- Jaypee Infratech: NBCC's resolution plan for Jaypee Infratech cleared by Committee of Creditors.
- TCS: Company received order from US-based Petco for merchandising platform.
- PC Jeweller: Promoter Padam Chand Gupta violated insider trading rules
- HFCL: Company completed acquisition of balance 50.10 percent of equity shares in DragonWave HFCL India.
- Goodyear India: Company will close manufacturing operations plant at Ballabgar, Haryana from December 21-30.
- NMDC: Company gets 20-year extension for four iron ore mines
- Piramal Enterprises: Rockefeller Foundation and Piramal join hands to improve health in India's tribal districts
- L&T Finance: Company raises Rs 1,503 cr in early closure of public issue of bonds
- Ajanta Pharma: Company gets US FDA nod for hypertension drug, Captopril Tablet (12.5-100 Mg)
- Bank of Baroda: FY19 gross & net NPA divergence at Rs 5,250 crore each. FY19 divergence in provisions at Rs 4,090 crore.
- Alembic Pharma: Company gets tentative US FDA nod for antipsychotic drug, asenapine tablet
- HDFC reappoints Renu Sud Karnad as MD w.e.f January 1, 2020
- Future Supply board approved allotment of 37.89 lakh equity shares to Nippon Express at Rs 664 per share
- Amid falling collections, FinMin sets Rs 1.1 trillion monthly GST target
- JSPL hopes to become debt free in 4 yrs: Naveen Jindal
- Patanjali gets one more week to complete Rs 4,350-cr Ruchi Soya deal
- Tata Motors expects turnaround in CV sales by second half of next fiscal

Global Indices	Current Value	%1D
DowJones	28267	0.11
Nasdaq	8823	0.10
DAX	13287	-0.89
Nikkei 225	23994	-0.30
FTSE 100	7525	0.08
Hang Seng	27843	-0.01
Shanghai	3026	0.12
Straits Times	3200	-0.01

Trading activity in cash Rs Cr			
Date 17 Dec	Net	MTD	FY20
FII	1248	-1753	-6943
DII	-908	2567	57143

Forex Rate		
USD/INR	70.94	-0.06%
EUR/INR	79.00	-0.21%
GBP/INR	94.96	-0.79%
JPY/INR	64.85	0.14%

### Corporate Action

Stock Name	Purpose	Ex Date
BOROSIL	Dividend Rs 0.65	18-Dec
IBVenture	Buy Back of Shares	18-Dec
INFRADEL	Interim Div Rs 2.75	19-Dec
ABB	Sin off	20-Dec

G-Sec Yield	Price	Change%
1yr Bond Yield	5.56	-0.71%
10yr Bond Yield	6.74	-0.74%

### Global News

Wall Street's major indexes inched higher on Tuesday, extending their record-setting rally, as strong housing and manufacturing data bolstered investors' confidence in the US economy. The Dow Jones Industrial Average rose 31.27 points, or 0.11%, to 28,267.16, the S&P 500 gained 1.07 points, or 0.03%, to 3,192.52 and the Nasdaq Composite added 9.13 points, or 0.1%, to 8,823.36. Asian stocks took a breather at 18-month peaks on Wednesday having climbed for five straight sessions, while the British pound was licking its wounds as revived Brexit fears came back to bite it.

### Results Calender 18-Dec-19

NIL

### F&O Ban List

YESBANK



# MSEARCH

## MORNING NEWSLETTER

**Disclaimer: Investments in securities market are subject to market risks, read all the related documents carefully before investing.**

Mehta Equities Limited (MEL) has used information that is publically available and information developed in-house. Some of the information used in the document may have been obtained from members/persons other than the MEL and/or its affiliates and which may have been made available to MEL and/or its affiliates. MEL however does not warrant the accuracy, reasonableness and/or completeness of any information and does not take responsibility of updating any data/information. For data reference to any third party in this material, no such party will assume any liability for the same. All data/information used in preparation of this material is dated and may or may not be relevant at any time after the issuance of this material. MEL (including its affiliates) and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any arising from the use of this material in any manner. Nothing contained in this document shall be construed to be an investment advice/recommendation on an assurance of the benefits of investing. Recipient alone shall be fully responsible for any investment decision taken on the basis of this document.

### MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478  
MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India  
Tel: +91 22 6150 7101, Fax: +91 22 6150 7102  
Email:[info@mehtagroup.in](mailto:info@mehtagroup.in) Website:[www.mehtagroup.in](http://www.mehtagroup.in)